For Immediate Release
Chicago, IL – December 10, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. LLY, AbbVie Inc. ABBV, Gilead Sciences, Inc. GILD, Air T, Inc. AIRT and Fossil Group, Inc. FOSL.
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Eli Lilly, AbVie and Gilead Sciences
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., AbbVie Inc. and Gilead Sciences, Inc., as well as two micro-cap stocks, Air T, Inc. and Fossil Group, Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Eli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+41.5% vs. +12.8%), reflecting the strong demand for Mounjaro and Zepbound. The company has received approvals for several new drugs like Kisunla, Omvoh and Jaypirca. Lilly is also making rapid pipeline progress in areas like obesity, diabetes and Alzheimer’s.
However, declining sales of Trulicity is a major headwind..
(You can read the full research report on Eli Lilly here >>>)
AbbVie shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past two years (+6.6% vs. +17.7%). The Zacks analyst believes that the company faces several near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on Imbruvica and slow market growth trend for Juvederm fillers in the United States and China.
Yet, Skyrizi and Rinvoq are performing extremely well, bolstered by approvals in new indications, which should support top-line growth in the next few years. AbbVie has several early/mid-stage candidates that have the potential to drive long-term growth.
(You can read the full research report on AbbVie here >>>)
Shares of Gilead Sciences have outperformed the Zacks Medical – Biomedical and Genetics industry over the last six months (+41.2% vs. -1.8%). Per the Zacks analyst, the company’s efforts to develop better HIV treatments are commendable. Lenacapavir’s data readout impresses investors. Substantial growth in Yescarta and Tecartus, along with the strong uptake of Trodelvy, has strengthened its oncology franchise.
However, recent pipeline setbacks weigh on Gilead.
(You can read the full research report on Gilead Sciences here >>>)
Air T’s shares have outperformed the Zacks Transportation – Air Freight and Cargo industry over the past year (+34.1% vs. -11.6%). The Zacks analyst believes that the company’s overnight Air Cargo segment, primarily serving FedEx, is a major growth driver, aided by fleet expansion and stable demand. Its asset-light model lowers operational risk. Strength in air cargo and commercial jet engines and parts and a sole-source deicer supply contract with the U.S. Air Force aid.
Yet, rising operating losses, inventory write-downs, high debt and a shrinking order backlog in Ground Equipment Sales signal challenges and potential pressure on future performance. Joint ventures (JVs) in aircraft asset management offer upside potential. Key customer dependence and seasonal risks add to concerns.
(You can read the full research report on Air T here >>>)
Fossil Group’s shares have outperformed the Zacks Retail – Apparel and Shoes industry over the past year (+61.5% vs. +39.5%). The Zacks analyst believes that SKU rationalization, pricing adjustments and exiting the lower-margin smartwatch category under the TAG Plan have benefited the company. Strategic exits from the smartwatch category and store closures have optimized operations, contributing to gross margin gains.
Yet, declining net sales due to strategic shifts, pressure on licensed watch brands and high debt levels present ongoing challenges.
(You can read the full research report on Fossil Group here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks Naming Top 10 Stocks for 2025
Want to be tipped off early to our 10 top picks for the entirety of 2025?
History suggests their performance could be sensational.
From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
Fossil Group, Inc. (FOSL) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
Air T, Inc. (AIRT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
